AI & ML · Jun 8
When ML Models Enter the Drug Approval Chain: What Peer-Reviewed Research Says About AI in Pharmaceutical Regulation
A cluster of peer-reviewed PMC studies reveals that AI is now embedded across the full pharmaceutical regulatory lifecycle globally, creating accountability demands that most ML curricula have never addressed.
- AI is now active on both sides of pharmaceutical regulation: inside industry submissions and inside the regulatory science agencies use to evaluate them. Understanding both contexts is essential for ML practitioners in life sciences.
- Regulatory frameworks for AI in drug development vary significantly across jurisdictions. Model validation is not a one-time event but a jurisdiction-specific, ongoing compliance requirement.
- The PMC literature on this topic is publicly accessible and functions as a practical specification for what accountability-aware ML deployment looks like in a high-stakes regulated environment.